CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
Taselisib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02785913
NCT02785913Phase 2Completed
CompareCT.gov

A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

SWOG Cancer Research Network·interventional·Posted May 30, 2016·Updated Oct 23, 2020

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Taselisib for Recurrent Squamous Cell Lung Carcinoma and Stage IV Squamous Cell Lung Carcinoma. Completed, enrolled 31 participants across 1,111 sites in 2 countries.

Detailed Summary

This phase II trial studies how well taselisib (GDC-0032) works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for the phosphoinositide 3-kinase (PI3K) biomarker. PI3K can cause tumor cells to grow more quickly. Taselisib may decrease the activity of PI3K and may be able to shrink tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma
CountriesCanada, United States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 30, 2016
Enrollment StartNov 1, 2014
Primary CompletionFeb 1, 2017
Study CompletionNov 1, 2019
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.1 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Taselisibdrug

Given PO